209
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients

, &
Pages 185-196 | Published online: 23 Jan 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Jürgen Scholze, Alexander Weinstock, Florian Kirchner, Roger Limberg & Reinhold Kreutz. (2014) Impact of socio-economic factors on the long-term effectiveness of antihypertensive treatment with an angiotensin II receptor blocker: an observational study. Current Medical Research and Opinion 30:10, pages 1947-1955.
Read now
Peter Bramlage, Claudia Zemmrich, Reinhard Ketelhut, Wolf-Peter Wolf, Eva-Maria Fronk & Roland E Schmieder. (2013) Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. Vascular Health and Risk Management 9, pages 475-483.
Read now
Juergen Scholze. (2011) Letter to the Editor. Expert Opinion on Drug Safety 10:3, pages 489-489.
Read now

Articles from other publishers (4)

Massimo Volpe, Giuliano Tocci, Alejandro de la Sierra, Reinhold Kreutz, Stéphane Laurent, Athanasios J. Manolis & Kostantinos Tsioufis. (2017) Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. High Blood Pressure & Cardiovascular Prevention 24:4, pages 463-472.
Crossref
Lars C. Rump, Bettina Ammentorp, Petra Laeis & Jürgen Scholze. (2015) Adding Hydrochlorothiazide to Olmesartan/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure Control on Dual‐Combination Therapy. The Journal of Clinical Hypertension 18:1, pages 60-69.
Crossref
T E Morozova, T B Andrushchishina & S V Gontarenko. (2014) Possibilities ARB II (sartans) in hypertensive patients. Systemic Hypertension 11:3, pages 33-38.
Crossref
Massimo Volpe & Giuliano Tocci. (2013) Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence. Drugs & Aging 30:12, pages 987-998.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.